Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Dianthus Therapeutics announces $400 million public stock offering
-
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
-
TD Cowen Reiterates Buy Rating on Dianthus Therapeutics (DNTH): "prime takeout target"
-
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
-
Dianthus Therapeutics to Participate in Four Investor Conferences During November
-
TD Cowen on Dianthus (DNTH): 'the favorable economics of the deal will not impact prior guidance of cash runway into 2028'
-
Dianthus Therapeutics closes $288 million public offering
-
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Dianthus Therapeutics prices $251 million public offering at $33 per share
-
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
-
Dianthus Therapeutics announces $150 million public offering
-
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
-
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
-
TD Cowen Starts Dianthus Therapeutics (DNTH) at Buy

